Trevena, Inc. (NASDAQ:TRVN) has earned an average recommendation of “Buy” from the thirteen brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $9.86.

A number of brokerages have commented on TRVN. Zacks Investment Research cut Trevena from a “hold” rating to a “sell” rating in a research report on Wednesday, July 26th. HC Wainwright cut their target price on Trevena from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, October 12th. Cowen and Company reiterated a “buy” rating and set a $10.00 target price on shares of Trevena in a research report on Friday, August 4th. Oppenheimer Holdings, Inc. set a $8.00 target price on Trevena and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, Barclays PLC cut Trevena from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $15.00 to $2.50 in a research report on Monday, October 16th.

ILLEGAL ACTIVITY NOTICE: “Trevena, Inc. (TRVN) Receives Average Recommendation of “Buy” from Analysts” was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/trevena-inc-trvn-receives-average-recommendation-of-buy-from-analysts/1679496.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Northpointe Capital LLC grew its holdings in Trevena by 5.0% during the 3rd quarter. Northpointe Capital LLC now owns 1,283,025 shares of the biopharmaceutical company’s stock valued at $3,272,000 after buying an additional 61,546 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Trevena by 40.4% during the 1st quarter. Bank of New York Mellon Corp now owns 231,553 shares of the biopharmaceutical company’s stock valued at $851,000 after buying an additional 66,577 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Trevena by 12.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 59,522 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 6,402 shares in the last quarter. SG Americas Securities LLC grew its holdings in Trevena by 81.0% during the 1st quarter. SG Americas Securities LLC now owns 35,926 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 16,079 shares in the last quarter. Finally, Bourgeon Capital Management LLC grew its holdings in Trevena by 56.8% during the 2nd quarter. Bourgeon Capital Management LLC now owns 53,031 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 19,200 shares in the last quarter. Institutional investors and hedge funds own 60.19% of the company’s stock.

Shares of Trevena (NASDAQ TRVN) opened at $1.48 on Friday. The company has a quick ratio of 7.15, a current ratio of 7.15 and a debt-to-equity ratio of 0.38. Trevena has a 1 year low of $1.38 and a 1 year high of $8.00.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, hitting analysts’ consensus estimates of ($0.35). research analysts anticipate that Trevena will post -1.27 EPS for the current fiscal year.

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.